The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature.

about

The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature.

Item

http://www.wikidata.org/entity/Q39455675

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The effect of apatinib in the ...... and review of the literature.

@en

The effect of apatinib in the ...... and review of the literature.

@nl

type

Item

label

The effect of apatinib in the ...... and review of the literature.

@en

The effect of apatinib in the ...... and review of the literature.

@nl

prefLabel

The effect of apatinib in the ...... and review of the literature.

@en

The effect of apatinib in the ...... and review of the literature.

@nl

P1476

The effect of apatinib in the ...... and review of the literature.

@en

P2093

Haiyuan Liu

http://www.w3.org/2001/XMLSchema#string

Jinling Bi

http://www.w3.org/2001/XMLSchema#string

Yong Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma

Apatinib for molecular targeted therapy in tumor

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.

P304

223-227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2147/IMCRJ.S137484

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28740436

http://www.w3.org/2001/XMLSchema#string

P932

5503666

http://www.w3.org/2001/XMLSchema#string